ELI LILLY & Co executive Melissa Seymour, EVP Global Quality, exercised 981 restricted stock units into an equal number of common shares on August 1, 2026. To satisfy exercise price or tax obligations, 438.707 shares were withheld at $1,148.8400 per share, and 952 RSUs remain scheduled to vest on August 1, 2027.
Eli Lilly and Company reports ownership of common stock of Ionetix Corp, a Delaware corporation with principal offices in Lansing, Michigan. Eli Lilly beneficially owns 8,411,397 shares of Ionetix common stock, representing 7.98% of the class.
Eli Lilly has sole power to vote and to dispose of all 8,411,397 shares, with no shared voting or dispositive power disclosed. The filing is signed by Christopher Anderson, Vice President – Leader of Corporate Securities and Assistant Corporate Secretary, on July 24, 2026.
ELI LILLY & Co reported its initial beneficial ownership in Scribe Therapeutics, Inc. (SCTX) as a 10% owner. It holds 1,054,828 shares of Common Stock on a direct basis. The company states that, after the closing of Scribe Therapeutics' initial public offering, it will cease to be a 10% owner and will no longer have Section 16 reporting obligations.
Lilly Endowment, Inc., an Indiana not-for-profit private foundation described under Section 501(c)(3) and classified as a private foundation under Section 509(a), reports beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock as of June 30, 2026.
This position represents 9.6% of Eli Lilly's common stock, based on 941,741,406 shares outstanding as of April 27, 2026, as reported in Eli Lilly's Form 10-Q for the period ended March 31, 2026. Lilly Endowment has sole voting power and sole dispositive power over all 90,376,978 shares, with no shared voting or dispositive power.
ELI LILLY & Co director Gabrielle Sulzberger reported a grant/award acquisition of 4.3232 shares of common stock on July 20, 2026 at $1,146.90 per share. At her election, this amount was deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in shares after her separation from service. Following this award, she directly holds 2,999.7188 shares of Eli Lilly common stock.
LUCIANO JUAN R reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Juan R Luciano received a grant of 13.878 shares of common stock on 2026-07-20 at $1,146.9000 per share. These shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in common shares after his separation from service. Following this award, he directly holds 16,904.5921 shares.
Fyrwald J Erik reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly director J Erik Fyrwald elected to receive 8.6465 shares’ worth of common stock on July 20, 2026 as deferred stock units in lieu of cash director compensation at $1,146.90 per share, bringing his direct holdings to 75,409.7433 shares, to be settled after his separation from service.
Alvarez Ralph reported acquisition or exercise transactions in this Form 4 filing.
ELI LILLY & Co director Ralph Alvarez received an award of 10.8263 common shares on 2026-07-20, valued at $1146.9000 per share. At his election, the award was deferred as stock units under the Lilly Directors' Deferral Plan, to be settled in shares after separation from service. Following this grant, he holds 55734.2935 shares directly and 758.0000 shares indirectly through a trust, for which he disclaims beneficial ownership beyond his pecuniary interest. The report indicates the transaction was not made under a Rule 10b5-1 trading plan.
The filer submitted a Form 144 notice reporting proposed sales of Eli Lilly and Company common stock by Lilly Endowment Inc. and related holders. The excerpt lists multiple sale dates between 05/06/2026 and 06/26/2026 with individual share quantities and gross proceeds for each trade.
Eli Lilly and Company-related holders reported proposed and completed sales of Common Stock. The excerpt lists a proposed sale of 38,400,000 shares attributed to the J.K. Lilly Sr. Trust and multiple completed dispositions by Lilly Endowment Inc., with dated transactions in May–June 2026 showing specific share counts and proceeds.